Trevi Therapeutics Execs to Present at Key Industry Conferences in June and July
Event summary
- Trevi Therapeutics executives to attend BIO International Convention (June 22-25), Leerink Partners Therapeutics Forum (July 14-15), and ERS Cough Conference (July 15-17).
- Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO, to represent Trevi at BIO International Convention.
- David Hastings, CFO, and Farrell Simon, Pharm.D., CCO, to present at Leerink Partners Therapeutics Forum.
- Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO, to attend ERS Cough Conference in London.
The big picture
Trevi Therapeutics is positioning itself as a key player in the chronic cough treatment space, targeting high-unmet needs in IPF, non-IPF ILD, and RCC. The company's upcoming presentations at major industry conferences are strategic moves to engage with investors and clinical experts, potentially accelerating Haduvio's path to market. With no FDA-approved therapies currently available for these conditions, Trevi's progress could significantly impact the treatment landscape.
What we're watching
- Clinical Progress
- How Trevi's presentations will highlight Haduvio's clinical trial results and regulatory strategy.
- Investor Sentiment
- Whether the upcoming investor forums will boost confidence in Trevi's pipeline and financial outlook.
- Competitive Positioning
- The pace at which Trevi can differentiate Haduvio in the chronic cough treatment landscape.